Taking everything into account, EXOZ scores 1 out of 10 in our fundamental rating. EXOZ was compared to 525 industry peers in the Biotechnology industry. The financial health of EXOZ is average, but there are quite some concerns on its profitability. EXOZ is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

EXOZ had negative earnings in the past year.
In the past year EXOZ has reported a negative cash flow from operations.

1.2 Ratios

EXOZ has a worse Return On Assets (-108.04%) than 76.38% of its industry peers.
With a Return On Equity value of -155.17%, EXOZ is not doing good in the industry: 64.38% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-108.04%
ROE	-155.17%
ROIC	N/A

ROA(3y)-51.41%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EXOZ so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for EXOZ has been increased compared to 1 year ago.
There is no outstanding debt for EXOZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

EXOZ has an Altman-Z score of 18.39. This indicates that EXOZ is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 18.39, EXOZ belongs to the top of the industry, outperforming 87.81% of the companies in the same industry.
EXOZ has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
EXOZ has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: EXOZ outperforms 44.57% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	18.39

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

EXOZ has a Current Ratio of 4.53. This indicates that EXOZ is financially healthy and has no problem in meeting its short term obligations.
EXOZ has a Current ratio (4.53) which is comparable to the rest of the industry.
A Quick Ratio of 4.53 indicates that EXOZ has no problem at all paying its short term obligations.
EXOZ's Quick ratio of 4.53 is in line compared to the rest of the industry. EXOZ outperforms 53.90% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.53
Quick Ratio	4.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EXOZ have decreased strongly by -256.10% in the last year.

EPS 1Y (TTM)-256.1%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-33.81%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EXOZ. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EXOZ!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

EXOZYMES INC

NASDAQ:EXOZ (1/21/2026, 8:14:14 PM)

Premarket: 11.6 0 (0%)

11.6

+0.54 (+4.88%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2025-11-13

Earnings (Next)03-31 2026-03-31

Inst Owners0.71%

Inst Owner ChangeN/A

Ins Owners24.86%

Ins Owner Change0%

Market Cap97.32M

Revenue(TTM)N/A

Net Income(TTM)-8.34M

AnalystsN/A

Price TargetN/A

Short Float %0.42%

Short Ratio2.47

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	18.11
P/tB	18.11
EV/EBITDA	N/A

EPS(TTM)-1.76

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-1.26

FCFYN/A

OCF(TTM)-1.22

OCFYN/A

SpS0

BVpS0.64

TBVpS0.64

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-108.04%
ROE	-155.17%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-51.41%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	108.26%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.53
Quick Ratio	4.53
Altman-Z	18.39

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)140.25%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-256.1%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-33.81%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-230.26%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-505.75%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-620.26%

OCF growth 3YN/A

OCF growth 5YN/A

EXOZYMES INC / EXOZ FAQ

What is the ChartMill fundamental rating of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a fundamental rating of 1 / 10 to EXOZ.

What is the valuation status of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a valuation rating of 0 / 10 to EXOZYMES INC (EXOZ). This can be considered as Overvalued.

What is the profitability of EXOZ stock?

EXOZYMES INC (EXOZ) has a profitability rating of 0 / 10.

Can you provide the financial health for EXOZ stock?

The financial health rating of EXOZYMES INC (EXOZ) is 5 / 10.